Drug Profile
Anti-mesothelin chimeric antigen receptor T cell therapy - Shanghai Genechem
Alternative Names: meso-CART - Shanghai Genechem; TAI-meso-CART - Shanghai GenechemLatest Information Update: 31 Oct 2021
Price :
$50
*
At a glance
- Originator Shanghai Genechem
- Class CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Pancreatic cancer
Most Recent Events
- 28 Apr 2019 No recent reports of development identified for phase-I development in Pancreatic-cancer(Late-stage disease, Second-line therapy or greater) in China (Infusion)
- 08 Mar 2016 Phase-I clinical trials in Pancreatic cancer (Second-line therapy or greater, Late-stage disease) in China (Infusion)